Core Insights - IP Strategy is the first Nasdaq-listed company to operate a digital asset treasury strategy centered on the $IP token, providing investors with exposure to the programmable intellectual property economy valued at $80 trillion [3] - The company held its inaugural Investor Day 2025, where it discussed its growth strategy and the convergence of AI, blockchain, and intellectual property [2][3] - Story, the blockchain network supporting the $IP token, has received $136 million in backing and launched its mainnet in February 2025, enabling the monetization of intellectual property in real time [5] Company Overview - IP Strategy operates a revenue-generating validator for the Story network and holds $IP tokens as a primary reserve asset [3] - The company aims to provide public market investors with a regulated equity format to participate in the Story ecosystem, which facilitates on-chain registration, licensing, and monetization of intellectual property [3] Industry Context - The Story network is described as an AI-native blockchain that makes intellectual property programmable and traceable, allowing creators to turn various forms of content into legally enforceable digital assets [5] - The convergence of AI, blockchain, and intellectual property is seen as a significant trend shaping a new investable asset class [2]

Atlanta, GA, Nov. 24, 2025 (GLOBE NEWSWIRE) -- ScanTech AI Systems Inc. (the "Company" or "ScanTech AI") (Nasdaq: STAI), a developer of advanced AI-powered security screening and imaging systems, today announced that it has entered into a non-binding term sheet with ARC Group International Ltd. (“ARC Group”) for a proposed $20 million subordinated convertible note facility financing (the “Proposed Financing”). The Company believes that this prospective financing will complement and operate alongside the Com ...

Core Insights - SEALSQ Corp has appointed Dr. Ballester Lafuente as Chief of Staff and Group AI Officer to enhance the integration of artificial intelligence across its operations and product lines [1][3][8] - Dr. Lafuente's role will focus on driving operational efficiency, innovation, and smarter processes within the company's semiconductor, PKI, IoT, satellite, and post-quantum technology sectors [3][8] - The company aims to leverage Dr. Lafuente's expertise in AI and digital innovation to scale operational excellence and enhance product offerings, positioning itself as a leader in trusted, quantum-resistant digital infrastructures [8][9] Company Overview - SEALSQ specializes in developing and selling semiconductors, PKI, and post-quantum technology hardware and software products [1][9] - The company is pioneering post-quantum semiconductors designed to provide robust protection against quantum computing threats, addressing urgent security challenges in various applications [9][10] - SEALSQ's technology integrates semiconductors with quantum-resistant cryptography, ensuring organizations remain secure against evolving quantum threats [10] Leadership Background - Dr. Ballester Lafuente previously served as Head of IT Innovation at IMD, where he led technology innovation strategy and AI platforms [4] - His experience includes roles at the EPFL Center for Digital Trust and co-founding MobileThinking SARL, focusing on digital trust and cybersecurity initiatives [5][6] - Dr. Lafuente holds advanced degrees in Management Information Systems, Security and Mobile Computing, and Computer Science, equipping him with a strong foundation for his new role [7]

Core Viewpoint - Akebia Therapeutics, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference, highlighting its commitment to addressing kidney disease [1][2]. Company Overview - Akebia Therapeutics is a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease, founded in 2007 and headquartered in Cambridge, Massachusetts [3]. - The company is fully integrated, indicating a comprehensive approach to its biopharmaceutical endeavors [3]. Event Details - The Fireside Chat featuring Akebia's executive team is scheduled for December 2, 2025, at 4:30 PM EST [1]. - The Piper Sandler Healthcare Conference will occur from December 2-4, 2025, in New York City [2]. - A webcast of the presentation will be available on Akebia's website under the "Investors" section [2].

Core Viewpoint - American Rebel Holdings, Inc. has successfully met the Nasdaq Listing Rule 5550(b)(1) by achieving stockholders' equity of $3,378,257, thus remaining compliant and listed on The Nasdaq Capital Market [1][2]. Compliance Confirmation - The Nasdaq Hearings Panel confirmed compliance on November 21, 2025, following the Company's filing of its Quarterly Report on Form 10-Q for the period ended September 30, 2025 [2][5]. - The compliance determination was based on the Company's stockholders' equity exceeding the required $2.5 million threshold [2][5]. CEO Commentary - The CEO of American Rebel expressed that the compliance notice is a significant milestone for the Company and its stockholders, emphasizing the importance of a Nasdaq listing for liquidity and investor base expansion [3]. - The CEO acknowledged the support from Nasdaq, strategic partners, and stockholders during the compliance process, indicating a focus on long-term value creation moving forward [3]. Monitoring Period - Following the compliance confirmation, the Company will enter a mandatory one-year monitoring period, during which any future non-compliance will lead to immediate delisting without additional cure periods [5][6]. Improvement in Stockholders' Equity - The Company has shown significant improvement in stockholders' equity, moving from a deficit of approximately $(8.0) million as of March 31, 2025, to a positive equity of $3,378,257 by September 30, 2025, reflecting an improvement of roughly $11.4 million [11]. - This improvement is attributed to a series of strategic initiatives executed throughout 2025 to strengthen the balance sheet [7][8]. Company Overview - American Rebel Holdings, Inc. is a patriotic lifestyle brand that has expanded from designing and marketing branded safes to include products like American Rebel Light Beer, apparel, and accessories [9]. - The Company aims to grow within the premium light lager segment across the United States, leveraging experienced distribution partners [9].

Second 50 MW Phase Delivered on Time, Bringing Energized Capacity to 100 MW and Advancing Applied Digital’s AI Factory Campus Toward 400 MWDALLAS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Applied Digital (NASDAQ: APLD) today announced the successful and on-time Ready for Service (RFS) for the second phase (50 MW) at the first 100 megawatt (MW) building at Building 1 of its Polaris Forge 1 AI Factory Campus in Ellendale, North Dakota. After achieving this milestone, Building 1 now operates at its full 100 MW critic ...

Core Insights - NANO Nuclear Energy Inc. has signed a Feasibility Study Agreement with BaRupOn LLC to evaluate the deployment of multiple KRONOS MMR units to generate 1 GW of nuclear energy at the Liberty American Multi-Sourced Power and Innovation Hub in Texas [1][3][4] - The feasibility study will assess power demand, reactor integration, and site suitability for the KRONOS MMR units [2][6] - BaRupOn anticipates a significant power squeeze due to increasing compute demand, particularly from the tech industry, and is willing to co-invest in the construction of NANO Nuclear's microreactors [3][4] Company Overview - NANO Nuclear is focused on developing advanced nuclear micro modular reactors and clean energy solutions, positioning itself as a key player in the North American advanced reactor market [1][14] - The KRONOS MMR is a high-temperature, gas-cooled microreactor designed for modular deployment, capable of powering large industrial campuses and data centers [7][8] - The collaboration with BaRupOn is seen as a strategic opportunity to address the growing energy needs of high-energy-intensive sectors, particularly in the context of AI and data centers [4][8] Industry Context - The demand for electricity in the tech industry, especially for high-performance computing and data centers, is expected to double within the decade, creating a need for reliable, emission-free power sources [8][21] - The LAMP hub is designed to support advanced manufacturing and AI data centers, highlighting the intersection of energy development and technological innovation [6][13] - The feasibility study represents a significant milestone in NANO Nuclear's roadmap for commercial deployment and could lead to further multi-reactor agreements across the U.S. [11]

Core Points - Monster Beverage Corporation will host an investor meeting on December 2, 2025, to update on business and operations, available via live webcast [1] - The CEO and senior executives will participate in a fireside chat at the Morgan Stanley Global Consumer & Retail Conference on December 3, 2025, also available via live webcast [2] Company Overview - Monster Beverage Corporation is based in Corona, California, and operates primarily through its consolidated subsidiaries, focusing on the development and marketing of energy drinks and other beverages [3] - The company's product range includes various energy drink brands such as Monster Energy®, Java Monster®, and Reign® Total Body Fuel, as well as still and sparkling waters and craft beers [3]

Core Points - Liberty Defense Holdings Ltd. has formed a strategic partnership with Noble IQ to support the installation, training, and maintenance of its HEXWAVE™ threat detection system across the United States [1][2][3] - Noble IQ will provide 24/7 technical support to ensure optimal performance and system uptime for Liberty's customers [2][3] - The partnership aims to enhance customer satisfaction and support Liberty's growth strategy by ensuring professional service and training for HEXWAVE deployments [3] Company Overview - Liberty Defense specializes in AI-based detection solutions for concealed weapons and threats, focusing on high-traffic areas requiring enhanced security [5][6] - The HEXWAVE product utilizes advanced 3D radar imaging technology and is designed for discreet, modular, and scalable protection against both metallic and non-metallic weapons [5][6] - Liberty has also licensed additional technologies, including millimeter wave-based body and shoe scanners, to expand its security solutions portfolio [6] Meeting Notice - An amendment has been made to the Company's Notice of Meeting regarding the date for shareholders of record, now set for November 6, 2025 [4]

Core Insights - The updated three-year results from the FIREFLY-1 trial demonstrate that 77% of patients who entered a treatment-free observation period after OJEMDA treatment remained off therapy for at least 12 months [1][5] - The median time to next treatment (TTNT) following the initiation of OJEMDA exceeded 3.5 years [1][5] - Tovorafenib shows potential as a second-line standard of care for pediatric low-grade glioma (pLGG) [3][4] Trial Results - In the FIREFLY-1 trial, 76 evaluable patients showed an overall response rate of 53% (40/76), with a median duration of response of 19.4 months [3][14] - The median time to response was 5.4 months, and the median progression-free survival was 16.6 months [3][5] - Among 39 patients who entered a treatment-free observation period, the median treatment-free interval was not reached, with minimal tumor rebound observed [5] Safety Profile - No new safety signals were identified in the updated analysis, with common grade 3 or higher adverse events including decreased growth velocity and anemia [6][14] - The most frequently reported adverse reactions (≥30%) included rash, fatigue, and viral infections [14][15] Regulatory Status - Tovorafenib (OJEMDA) is approved by the FDA for pediatric patients aged 6 months and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement [7][8] - The drug has received Breakthrough Therapy and Rare Pediatric Disease designations from the FDA [10] Industry Context - Pediatric low-grade glioma is the most common brain tumor in children, with significant unmet medical needs due to the lack of approved treatments targeting BRAF alterations [11][12] - The FIREFLY-1 trial is part of a broader effort to evaluate tovorafenib in pediatric patients with pLGG, highlighting the importance of targeted therapies in this demographic [13][18]